A detailed history of Geode Capital Management, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,937,948 shares of ARWR stock, worth $62.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,937,948
Previous 2,754,634 6.65%
Holding current value
$62.8 Million
Previous $78.8 Million 3.08%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$21.87 - $28.24 $4.01 Million - $5.18 Million
183,314 Added 6.65%
2,937,948 $76.4 Million
Q1 2024

May 13, 2024

BUY
$27.21 - $39.48 $11.6 Million - $16.9 Million
427,758 Added 18.38%
2,754,634 $78.8 Million
Q4 2023

Feb 13, 2024

BUY
$21.2 - $31.03 $2.3 Million - $3.37 Million
108,623 Added 4.9%
2,326,876 $71.2 Million
Q3 2023

Nov 13, 2023

BUY
$26.2 - $36.08 $1.71 Million - $2.35 Million
65,203 Added 3.03%
2,218,253 $59.6 Million
Q2 2023

Aug 11, 2023

BUY
$25.16 - $41.38 $1.87 Million - $3.08 Million
74,523 Added 3.59%
2,153,050 $76.8 Million
Q1 2023

May 15, 2023

BUY
$23.68 - $38.51 $2.49 Million - $4.04 Million
104,976 Added 5.32%
2,078,527 $52.8 Million
Q4 2022

Feb 13, 2023

BUY
$28.0 - $40.56 $2.41 Million - $3.49 Million
86,154 Added 4.56%
1,973,551 $80 Million
Q3 2022

Nov 14, 2022

BUY
$29.63 - $48.31 $1.07 Million - $1.74 Million
36,020 Added 1.95%
1,887,397 $62.4 Million
Q2 2022

Aug 12, 2022

SELL
$27.79 - $50.61 $98,765 - $179,867
-3,554 Reduced 0.19%
1,851,377 $65.2 Million
Q1 2022

May 13, 2022

BUY
$39.62 - $69.97 $1.55 Million - $2.73 Million
39,031 Added 2.15%
1,854,931 $85.3 Million
Q4 2021

Feb 11, 2022

BUY
$58.09 - $82.51 $1.48 Million - $2.11 Million
25,523 Added 1.43%
1,815,900 $120 Million
Q3 2021

Nov 12, 2021

SELL
$58.38 - $84.96 $1.08 Million - $1.57 Million
-18,425 Reduced 1.02%
1,790,377 $112 Million
Q2 2021

Aug 13, 2021

BUY
$62.15 - $90.32 $3.25 Million - $4.72 Million
52,292 Added 2.98%
1,808,802 $150 Million
Q1 2021

May 12, 2021

BUY
$61.35 - $90.47 $9.09 Million - $13.4 Million
148,237 Added 9.22%
1,756,510 $116 Million
Q4 2020

Feb 12, 2021

BUY
$43.82 - $85.37 $3.51 Million - $6.83 Million
80,045 Added 5.24%
1,608,273 $123 Million
Q3 2020

Nov 13, 2020

SELL
$33.21 - $51.27 $871,031 - $1.34 Million
-26,228 Reduced 1.69%
1,528,228 $65.8 Million
Q2 2020

Aug 13, 2020

BUY
$26.12 - $43.27 $1.01 Million - $1.68 Million
38,813 Added 2.56%
1,554,456 $67.2 Million
Q1 2020

May 14, 2020

BUY
$20.56 - $63.12 $1.71 Million - $5.26 Million
83,282 Added 5.81%
1,515,643 $43.6 Million
Q4 2019

Feb 13, 2020

BUY
$28.14 - $73.01 $3.25 Million - $8.44 Million
115,576 Added 8.78%
1,432,361 $90.9 Million
Q3 2019

Nov 12, 2019

BUY
$26.26 - $34.86 $892,813 - $1.19 Million
33,999 Added 2.65%
1,316,785 $37.1 Million
Q2 2019

Aug 14, 2019

BUY
$17.43 - $28.82 $2.09 Million - $3.46 Million
120,083 Added 10.33%
1,282,786 $34 Million
Q1 2019

May 14, 2019

BUY
$12.05 - $20.18 $2 Million - $3.35 Million
166,245 Added 16.68%
1,162,703 $21.3 Million
Q4 2018

Feb 13, 2019

BUY
$10.74 - $19.7 $797,928 - $1.46 Million
74,295 Added 8.06%
996,458 $12.4 Million
Q3 2018

Nov 13, 2018

BUY
$14.0 - $20.3 $675,514 - $979,495
48,251 Added 5.52%
922,163 $17.7 Million
Q2 2018

Aug 14, 2018

BUY
$6.37 - $14.02 $1.55 Million - $3.41 Million
243,281 Added 38.58%
873,912 $11.9 Million
Q1 2018

May 15, 2018

BUY
$3.72 - $7.64 $105,220 - $216,097
28,285 Added 4.7%
630,631 $4.55 Million
Q4 2017

Feb 13, 2018

SELL
$3.14 - $4.5 $54,585 - $78,228
-17,384 Reduced 2.81%
602,346 $2.22 Million
Q3 2017

Nov 14, 2017

BUY
$1.69 - $4.33 $101,405 - $259,812
60,003 Added 10.72%
619,730 $2.68 Million
Q2 2017

Aug 14, 2017

BUY
N/A
559,727
559,727 $906,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.26B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.